The Tyrosine Protein Kinase Receptor TYRO3 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase Receptor TYRO3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase Receptor TYRO3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Bladder Cancer, and Non-Small Cell Lung Cancer. It also reviews key players involved in Tyrosine Protein Kinase Receptor TYRO3 targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase Receptor TYRO3 pipeline targets constitutes close to 12 molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, and Preclinical stages are 1, 2, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 4 molecule.
Tyrosine Protein Kinase Receptor TYRO3 overview
Tyrosine-protein kinase receptor TYRO3 is an enzyme encoded by the TYRO3 gene. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 signaling plays an important role in various processes such as neuron protection from excitotoxic injury, platelet aggregation, cytoskeleton reorganization, inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.
For a complete picture of Tyrosine Protein Kinase Receptor TYRO3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
